Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Roquefort Investments PLC ( (GB:ROQ) ).
Roquefort Therapeutics PLC announced updates on two significant corporate transactions and its forward strategy. The company is selling its subsidiary Lyramid Pty Ltd to Pleiades Pharma Limited for $10.8 million, contingent on Pleiades completing certain licensing and fundraising conditions. Additionally, Roquefort is negotiating the sale of its subsidiary Oncogeni Ltd to The Nation Trust Holding LLC for up to $12 million. These transactions are part of Roquefort’s strategy to pivot from pre-clinical assets to more mature, revenue-generating life science opportunities, aiming to capitalize on current market conditions and generate short-term value.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 2,748,484
Technical Sentiment Signal: Sell
Current Market Cap: £2.56M
For a thorough assessment of ROQ stock, go to TipRanks’ Stock Analysis page.